NAD+ and peptides: how longevity clinicians are combining protocols

Two separate areas of longevity research are increasingly used together. Here’s the rationale — and an honest look at what’s proven vs. what’s theoretical.

TL;DR

• NAD+ and peptides are different compounds that work through different mechanisms, but some longevity clinicians use them together.
• The rationale is mechanistic — both affect cellular repair processes — but head-to-head combination trials don’t exist yet.
• The science on each individually is stronger than the science on combining them.

What it is

NAD+ (nicotinamide adenine dinucleotide — a coenzyme, or helper molecule, that cells use to produce energy and repair DNA) declines as we age. NAD+ precursors — NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) — are supplements studied for their ability to raise NAD+ levels. Think of NAD+ as the cellular battery. Precursors are the charger.

Peptides, separately, are short chains of amino acids that act as signaling molecules — keys that turn specific biological locks. Some peptides are studied in the context of tissue repair, cellular communication, and aging-related decline.

How they’re being combined

Longevity-focused clinicians who use both describe a mechanistic complement. NAD+ precursors may support the energy infrastructure inside cells (mitochondria — the cell’s power plants). Some peptides studied in healthy-aging contexts, like BPC-157, have been linked in the preclinical literature to tissue repair and cellular communication. The logic: if cells have more energy to run repair processes, repair-signaling compounds may work more effectively.

This is theoretical reasoning, not a completed clinical trial. No published human study has tested the combination directly.

Who asks about it

People already using one approach who wonder whether adding the other makes sense — or people building a longevity protocol and trying to understand how practitioners structure these decisions.

What the research says

NAD+ precursors have a growing human evidence base. A 2022 study published in Nature Aging found NMN supplementation improved muscle insulin sensitivity and other markers in older adults (PMID 34906400). Sirtuins — proteins that NAD+ activates — are studied for roles in DNA repair and cellular stress response. The peptide literature separately shows preclinical research on tissue repair and cellular protection. Combining the two is a clinical practice emerging from mechanistic reasoning.

What to know before considering it

NAD+ precursors and peptides are distinct protocols with distinct monitoring needs. Combining them multiplies the variables. Baseline biomarkers — including IGF-1 if growth hormone peptides are involved — help clinicians track whether a protocol is having its intended effect without unwanted signals. See our biomarker monitoring overview.

The Halftime POV

We think the NAD+ and peptide space is one of the more interesting areas in longevity medicine precisely because the mechanisms make biological sense. What we don’t do is overstate the evidence. Each person’s protocol should start with clear baseline data and build from what’s individually indicated — not from what a podcast says works for everyone.

Related reading:

• Autophagy: the cellular cleanup process that longevity researchers keep coming back to
• Cellular senescence and senolytics: what the longevity research shows
• Biomarkers to track during a peptide protocol

FAQ

Q: What is NAD+ and why does it matter for aging? A: NAD+ is a coenzyme essential for cellular energy production and DNA repair. Levels decline with age. Raising NAD+ is studied as a way to support cellular function in older adults.

Q: Can you take NAD+ and peptides at the same time? A: Some longevity clinicians use both. There’s no known interaction that makes the combination unsafe, but there are also no controlled human trials on the combination. The rationale is mechanistic. A clinician can help evaluate whether both are appropriate for a specific individual.

Q: Is NAD+ a peptide? A: No. NAD+ is a coenzyme, not a peptide. Peptides are chains of amino acids. The two are distinct compounds with different mechanisms and different access routes.

Disclaimer

This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.

Get updates

Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.

Sources

• Yoshino M et al., “Nicotinamide mononucleotide increases muscle insulin sensitivity,” Science, 2021
• NIH NIA — NAD and Aging Research

This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health’s published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.